Several angel investors also participated in the Series A fundraise. Nudge launched its first product earlier this year, the Nudge Zero, a non-invasive ultrasound neuromodulation device. The product uses ultrasound technology to modify brain activity in a way that impacts cell membranes in the brain without causing permanent changes or damage. “We’ve raised a $100M Series A from Thrive Capital, Greenoaks, and a host of great angels,” Ehrsam wrote in a post on X. “Everyone’s brain can work better. Engineering that idea into reality is the most impactful advancement we can make to life.”

免责声明：本文章仅代表作者个人观点，不代表本平台的立场和观点。本文章仅供信息分享，不构成对任何人的任何投资建议。用户与作者之间的任何争议，与本平台无关。如网页中刊载的文章或图片涉及侵权，请提供相关的权利证明和身份证明发送邮件到support@aicoin.com，本平台相关工作人员将会进行核查。